Fresenius Medical Care AG & Co KGaA (Fresenius Medical Care) is a renal therapy company which provides dialysis services and products and equipment for the treatment of end-stage renal disease (ESRD). It develops and manufactures a comprehensive range of renal care equipment, systems and disposable products. The company also offers Care Coordination services including pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services, and urgent care services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Fresenius Medical Care conducts research to develop and advance new products and therapies. The company has facilities in in Schweinfurt, Bad Homburg v. d. Hohe, St. Wendel, and Palazzo Pignano in Europe, as well as Ogden, Utah, in the US, and Shanghai and Changshu in China. The company undertook several R&D initiatives in FY2025, focusing on improving care for patients with end-stage kidney disease (ESKD) and advancing nephrology. Its major initiatives included advancements in dialysis technology, personalized therapy, and artificial intelligence applications. The company emphasized high-volume hemodiafiltration (HVHDF) and clinical validation, with significant progress in clinical trials such as the SARCA Study and the MFT PRO Adult Study. The Renal Research Institute developed AI applications for precision nutrition and home dialysis prediction, while biomarker research focused on metabolomics and proteomics. The company also strengthened global research partnerships and launched new products, emphasizing digitalization and sustainability in healthcare. The Renal Research Institute is a key R&D unit of Fresenius Medical Care, focusing on data-driven research, artificial intelligence, and advanced analytics in nephrology. The Global Medical Office supports commercialization and clinical research, while Fresenius Medical Care Ventures collaborates with start-ups to promote innovation. In FY2025, the company spent EUR157.9 million on its R&D activities, which as a percentage of revenue stood at 1%. As of December 2025, the company held approximately 7,890 patents across 1,498 patent families. Major technology alliances include collaborations with institutions such as Mayo Clinic, Imperial College London, and Massachusetts General Hospital.